Routine CMO appointment with no change in business outlook. The inducement stock grant at-the-money signals management's confidence in pipeline progression but creates modest future dilution (~150k shares). Monitor upcoming Phase 3 data readouts for fasedienol (social anxiety disorder) as the primary catalyst for VTGN.
Price Chart
Executive Summary
Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000, a $50,000 signing bonus, and an inducement stock option for 150,000 shares at $0.5955/share. This is a routine C-level appointment that fills a key clinical leadership role for a late-stage biopharmaceutical company focused on Phase 3 fasedienol for social anxiety disorder.
Key Facts
- Appointed Angel S. Angelov, MD, MBA as Chief Medical Officer effective May 18, 2026
- Annual base salary of $425,000; eligible for annual discretionary cash bonus with initial target of 45% of base salary
- Received $50,000 signing bonus (50% upon start, 50% at six-month anniversary)
- Granted inducement stock option to purchase 150,000 shares at $0.5955 per share (closing price on May 18, 2026)
- Option vests 25% on one-year anniversary, remainder monthly over 36 months; 10-year term
- Company entered into standard indemnification agreement with Dr. Angelov
- Dr. Angelov previously served as CMO at Theranica and held VP-level roles at Karuna Therapeutics, Neurocrine Biosciences
Financial Impact
Compensation costs of $425k salary plus $50k signing bonus; option grant of 150k shares represents approximately 1.4% dilution based on $24M market cap and $0.5955 option price (implied shares outstanding ~40M)
Risk Factors
- No new clinical data or pipeline catalysts in this filing
- Inducement grants add to shareholder dilution over next 4 years
- Company is pre-revenue clinical-stage with $24M market cap — limited margin for error on Phase 3 trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-036492 |
| Document: vtgn-20260518.htm | 0001628280-26-036492 |
| Document: vtgn8-kex99120260519.htm | 0001628280-26-036492 |
| Document: 0001628280-26-036492-index-headers.html | 0001628280-26-036492 |
| Document: 0001628280-26-036492-index.html | 0001628280-26-036492 |
| Document: 0001628280-26-036492.txt | 0001628280-26-036492 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2847 (−6.39%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2847 (+6.39%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2847 (+18.13%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2847 (−25.97%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2847 (−57.52%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2847 (−58.74%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2847 (−50.32%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2847 (−46.79%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2847 (−55.52%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2847 (−54.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access